The first of a new kind of disease-modifying antirheumatic drug, Jakinibs or JAK inhibitors, was approved in 2012. Sometimes called “oral biologics,” they're given as pills rather than as a shot or an infusion, as with the other biologics. Jakinibs work from inside the cells to block the enzymes that alert the immune system to an invader.